Accentia, Biovest emerge from bankruptcy

Two years after filing for bankruptcy, Accentia Biopharmaceuticals and Biovest International are emerging from the ashes. The U.S. Bankruptcy Court for the Middle District of Florida, Tampa Division approved the companies' reorganization plan, which was filed in June.

The plan includes $7 million in financing from Biovest, Accentia's majority-owned subsidiary, as well as other debt restructuring and expense reduction. "[This] represents the completion of the financial and business restructuring that, I believe, is critical to maximizing the opportunities represented by our long-term strategic growth plans," said Samuel Duffey, Accentia's President and General Counsel, in a release. The company will continue to pursue treatments for autoimmune disease and cancer vaccines, with its products Revimmune and BiovaxID, respectively.

- see the Accentia/Biovest release
- and here's the Tampa Bay Business Journal's coverage

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.